Form 4: Oramed Pharmaceuticals COO & CBO, Joshua Hexter, Acquires 194,500 Restricted Stock Units
SEC Form 4
Oramed Pharmaceuticals' COO & CBO, Joshua Hexter, has acquired 194,500 restricted stock units, which will vest over a three-year period.
Summary
- Joshua Hexter, the COO & CBO of Oramed Pharmaceuticals, has reported a transaction involving the acquisition of 194,500 restricted stock units (RSUs).
- These RSUs will vest in quarterly installments of approximately 16,208 over a three-year period, starting on January 1, 2025.
- The RSUs convert into Oramed Pharmaceuticals' common stock on a one-for-one basis.
- Following this transaction, Mr. Hexter beneficially owns 706,333 shares of common stock.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with company performance. There are no negative implications.
Positives
- The acquisition of RSUs by a key executive like the COO & CBO can be seen as a positive sign of confidence in the company's future.
Industry Context
This type of stock-based compensation is common in the pharmaceutical industry to align executive interests with shareholder value and long-term company performance.
Comparison to Industry Standards
- Stock-based compensation, such as RSUs, is a standard practice for executive compensation in the pharmaceutical and biotech industries.
- Companies like Amgen, Gilead Sciences, and Regeneron often use similar equity-based incentives to attract and retain key talent.
- The vesting schedule of three years is also typical for such grants, ensuring long-term commitment from the executive.
Stakeholder Impact
- The acquisition of RSUs by a key executive can positively impact shareholder confidence.
- The vesting schedule ensures the executive's long-term commitment to the company's success.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the transaction where Joshua Hexter acquired the restricted stock units. |
| 01/01/2025 | Start date for the quarterly vesting of the restricted stock units. |
| 01/06/2025 | Date the form was signed by Joshua Hexter. |
Keywords
Oramed Pharmaceuticals, Restricted Stock Units, RSUs, Joshua Hexter, COO, CBO, Beneficial Ownership, Stock Options, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.